Clinical, genetic, and familial features of POT1 tumor predisposition syndrome
Cancer · 2026
DOI: 10.1002/cncr.70315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Courtney D DiNardo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Telomere-Binding Proteins, Genetic Predisposition to Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplastic Syndromes, Hereditary. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Protection of telomere 1 (POT1) tumor predisposition syndrome (POT1‐TPD) is a hereditary leukemia syndrome that is identified in ∼5% of patients with chronic lymphocytic leukemia (CLL) and is characterized by a predisposition to other cancers, including gliomas, melanomas, and angiosarcomas. This study reports clinical and genetic characteristics of a large cohort of individuals with POT1‐TPD. Materials and Methods Individuals with pathogenic/likely pathogenic germline POT1 variants referred to the Hereditary Hematologic Malignancy Clinic at The University of Texas MD Anderson Cancer Center were included. Individuals with variants of uncertain significance were included if found to have telomeres >90th percentile of age‐predicted length.
Results
Twenty‐four individuals in 17 families were identified. At referral, 11 (46%) had CLL and one (4%) had monoclonal B‐cell lymphocytosis (MBL). The remaining 12 individuals had no history of CLL/MBL; however, four (33%) were discovered to have MBL at the time of referral. Among the 17 families, melanoma (47%), CLL (35%), and glioblastoma (18%) were prevalent. Five families had telomere length testing (31%), with lymphocyte telomere lengths >99th percentile in 60% and >90th percentile in 100%. Patients with CLL ( n = 11) had a median age at diagnosis of 55 years (range, 29–68). A total of 82% had diploid karyotype, 64% had del13q by fluorescence in situ hybridization, and 60% had mutated immunoglobulin heavy chain variable region. Five patients (45%) received treatment for CLL, with a median time‐to‐treatment of 4.5 years (95% CI, 4.3–4.6).
Conclusion
This analysis provides insights into the clinical features and familial patterns of malignancy of individuals with POT1‐TPD. Identification through genetic counseling and augmented cancer screening is paramount.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Courtney D DiNardo, Jennifer Croden, Tapan Kadia, Alexandre Bazinet, Prithviraj Bose, Fadi Haddad, Hagop Kantarjian
Zitieren
APA
DiNardo, C. D., Croden, J., Abdel-Salam, H. M., Kadia, T., Molica, M., Bazinet, A., Bose, P., Maiti, A., Haddad, F., Burger, J., Kantarjian, H., Wierda, W., Jain, N., & Ferrajoli, A. (2026). Clinical, genetic, and familial features of POT1 tumor predisposition syndrome. Cancer. https://doi.org/10.1002/cncr.70315
Vancouver
DiNardo CD, Croden J, Abdel-Salam HM, Kadia T, Molica M, Bazinet A, et al. Clinical, genetic, and familial features of POT1 tumor predisposition syndrome. Cancer. 2026. doi:10.1002/cncr.70315
BibTeX
@article{DiNardo2026,
author = {DiNardo, Courtney D and Croden, Jennifer and Abdel-Salam, Hiam M and Kadia, Tapan and Molica, Matteo and Bazinet, Alexandre and Bose, Prithviraj and Maiti, Abhishek and Haddad, Fadi and Burger, Jan and Kantarjian, Hagop and Wierda, William and Jain, Nitin and Ferrajoli, Alessandra},
title = {Clinical, genetic, and familial features of POT1 tumor predisposition syndrome},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70315}
}
EUVIMED